{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:12:27Z","timestamp":1788642747074,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2016909"],"award-info":[{"award-number":["2016909"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2025894"],"award-info":[{"award-number":["2025894"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Naloxone is an opioid overdose reversal drug that is available for free without a prescription via participating community pharmacies in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate Australian community pharmacists\u2019 knowledge, attitudes, practices, and provision of naloxone and overdose prevention, and identify barriers to and correlates of naloxone provision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Data were collected between January and April 2025 via an anonymous, cross-sectional questionnaire among Australian community pharmacists who were recruited using a randomised representative sampling approach. Data pertaining to pharmacy and pharmacist-related characteristics, pharmacists\u2019 knowledge and attitudes towards naloxone, overdose prevention, and provision of naloxone, including barriers to provision, were captured. Multivariable logistic regression was conducted to determine the pharmacy (including jurisdiction, geographic location, pharmacy type, and provision of other harm reduction services) and pharmacist (including gender, years of experience, knowledge of, and attitudes towards naloxone and overdose prevention) characteristics associated with stocking naloxone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 730 pharmacists who completed the online questionnaire, approximately three-quarters (n\u2009=\u2009534, 73.2%) stocked naloxone. Most pharmacists had positive attitudes towards naloxone (85%), and good or excellent self-reported knowledge (81%) of naloxone and overdose prevention. Logistic regression analyses revealed that pharmacies that had significantly greater odds of stocking naloxone were located in Australia\u2019s least populous states\/territories (Australian Capital Territory, Northern Territory, Tasmania, South Australia) (aOR: 2.32; 95% CIs 1.17\u20134.61) and Queensland (aOR: 2.12; 95% CIs 1.17\u20133.83), provided Opioid Agonist Treatment (aOR: 2.77; 95% CIs 1.82\u20134.24), and had pharmacists with good or excellent knowledge of naloxone (aOR: 4.43, CIs 2.75\u20137.12; aOR: 6.19, CIs 3.53\u201310.84 respectively) and very positive attitudes towards naloxone supply (aOR: 2.29, 95% CIs 1.23\u20135.25). Lack of time to develop, implement and\/or sustain the program (59.4%) and lack of training among pharmacy staff (44.6%) were identified as key barriers among the minority of pharmacists that did not stock naloxone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A large proportion of community pharmacies in Australia stocked naloxone, with variability across states\/territories. While pharmacists\u2019 attitudes and knowledge were positive overall, there remains scope to increase provision of adequate education and targeted support to strengthen community pharmacies\u2019 harm reduction capacity and provide equitable access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02219-8","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:39:51Z","timestamp":1788597591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Knowledge, attitudes and practices among Australian community pharmacists towards naloxone and overdose prevention: a national cross-sectional study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7593-3209","authenticated-orcid":false,"given":"Louisa","family":"Picco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Laing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Sproule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"2219_CR1","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2025. 2025. https:\/\/www.unodc.org\/documents\/data-and-analysis\/WDR_2025\/WDR25_B1_Key_findings.pdf. Accessed 03.12.2025."},{"issue":"8","key":"2219_CR2","doi-asserted-by":"publisher","first-page":"e0328276","DOI":"10.1371\/journal.pone.0328276","volume":"20","author":"DT Zhu","year":"1990","unstructured":"Zhu DT, Kwon YIC, Lai A, et al. Global burden of disease due to opioid, amphetamine, cocaine, and cannabis use disorders, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. PLoS ONE. 1990;20(8):e0328276. https:\/\/doi.org\/10.1371\/journal.pone.0328276.","journal-title":"PLoS ONE"},{"issue":"8","key":"2219_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.sapharm.2018.07.001","volume":"15","author":"S Lalic","year":"2019","unstructured":"Lalic S, Jokanovic N, Ilomaki J, et al. Harms associated with extramedical use of prescription opioid analgesics in Australia: a scoping review. Res Soc Adm Pharm. 2019;15(8):925\u201335. https:\/\/doi.org\/10.1016\/j.sapharm.2018.07.001.","journal-title":"Res Soc Adm Pharm"},{"issue":"2","key":"2219_CR4","first-page":"97","volume":"25","author":"L Manchikanti","year":"2022","unstructured":"Manchikanti L, Singh VM, Staats PS, et al. Fourth wave of opioid (illicit drug) overdose deaths and diminishing access to prescription opioids and interventional techniques: cause and effect. Pain Phys. 2022;25(2):97.","journal-title":"Pain Phys"},{"issue":"13","key":"2219_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s40265-019-01154-5","volume":"79","author":"J Strang","year":"2019","unstructured":"Strang J, McDonald R, Campbell G, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs. 2019;79(13):1395\u2013418. https:\/\/doi.org\/10.1007\/s40265-019-01154-5.","journal-title":"Drugs"},{"key":"2219_CR6","unstructured":"World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. 2025."},{"issue":"1","key":"2219_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/add.15163","volume":"116","author":"R Smart","year":"2021","unstructured":"Smart R, Pardo B, Davis CS. Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. Addiction. 2021;116(1):6\u201317. https:\/\/doi.org\/10.1111\/add.15163.","journal-title":"Addiction"},{"issue":"5","key":"2219_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3109\/09687637.2016.1150964","volume":"23","author":"R Dwyer","year":"2016","unstructured":"Dwyer R, Fraser S, Dietze P. Benefits and barriers to expanding the availability of take-home naloxone in Australia: a qualitative interview study with service providers. Drugs Educ Prev Policy. 2016;23(5):388\u201396. https:\/\/doi.org\/10.3109\/09687637.2016.1150964.","journal-title":"Drugs Educ Prev Policy"},{"key":"2219_CR9","unstructured":"Langford A, Schneider C, Lin C et al. Evidence-based Clinical Practice Guideline for Deprescribing Opioid Analgesics. The University of Sydney. 2022. https:\/\/www.opioiddeprescribingguideline.com\/_files\/ugd\/c86050_e0ed96b38d704cc88534bf1fb0fd028a.pdf. Accessed 13.09.2024."},{"issue":"3","key":"2219_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"D Dowell","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, et al. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022;71(3):1\u201395. https:\/\/doi.org\/10.15585\/mmwr.rr7103a1.","journal-title":"MMWR Recomm Rep"},{"key":"2219_CR11","unstructured":"Department of Health and Social Care. Supplying take home naloxone without a prescription. 2025. https:\/\/www.gov.uk\/guidance\/supplying-take-home-naloxone-without-a-prescription. Accessed 04.12.2025."},{"issue":"7","key":"2219_CR12","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/add.13326","volume":"111","author":"R McDonald","year":"2016","unstructured":"McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177\u201387. https:\/\/doi.org\/10.1111\/add.13326.","journal-title":"Addiction"},{"key":"2219_CR13","unstructured":"Moustaqim-Barrette A, Elton-Marshall T, Leece P et al. Environmental Scan Naloxone Access and Distribution in Canada. 2019."},{"key":"2219_CR14","unstructured":"Australian Government Department of Health Disability and Ageing. About the Take Home Naloxone program. 2025. https:\/\/www.health.gov.au\/our-work\/take-home-naloxone-program\/about-the-take-home-naloxone-program?language=en. Accessed 29.06.2026."},{"issue":"6","key":"2219_CR15","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1007\/s11096-024-01773-3","volume":"46","author":"R Laing","year":"2024","unstructured":"Laing R, Xia T, Grist E, et al. Correlates of stocking naloxone: a cross-sectional survey of community pharmacists. Int J Clin Pharm. 2024;46(6):1362\u201370. https:\/\/doi.org\/10.1007\/s11096-024-01773-3.","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"2219_CR16","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1111\/add.13517","volume":"111","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Menon N, Larney S, et al. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. Addiction. 2016;111(12):2177\u201386. https:\/\/doi.org\/10.1111\/add.13517.","journal-title":"Addiction"},{"issue":"1","key":"2219_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/29767342251351753","volume":"47","author":"T Rife-Pennington","year":"2026","unstructured":"Rife-Pennington T, Dinges B, Vu TT, et al. The missing dose: integrating harm reduction into pharmacy curriculums. Subst Use Addict J. 2026;47(1):9\u201314. https:\/\/doi.org\/10.1177\/29767342251351753.","journal-title":"Subst Use Addict J"},{"issue":"3","key":"2219_CR18","doi-asserted-by":"publisher","first-page":"e110929","DOI":"10.1136\/bmjopen-2025-110929","volume":"16","author":"J Navarrete","year":"2026","unstructured":"Navarrete J, Berg E, Hughes C, et al. Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff. BMJ Open. 2026;16(3):e110929. https:\/\/doi.org\/10.1136\/bmjopen-2025-110929.","journal-title":"BMJ Open"},{"issue":"1","key":"2219_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12954-025-01281-1","volume":"22","author":"S Flei\u00dfner","year":"2025","unstructured":"Flei\u00dfner S, Steimle L, Sch\u00e4ffer D, et al. The implementation of take-home naloxone: lessons learned from a 3-year take-home naloxone project in Germany. Harm Reduct J. 2025;22(1):120. https:\/\/doi.org\/10.1186\/s12954-025-01281-1.","journal-title":"Harm Reduct J"},{"issue":"9","key":"2219_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3238\/arztebl.m2025.0030","volume":"122","author":"S Flei\u00dfner","year":"2025","unstructured":"Flei\u00dfner S, St\u00f6ver H, Sch\u00e4ffer D, et al. Take-home naloxone in opioid dependency: an intervention to reduce opioid-related deaths. Dtsch Arztebl Int. 2025;122(9):240\u20134. https:\/\/doi.org\/10.3238\/arztebl.m2025.0030.","journal-title":"Dtsch Arztebl Int"},{"key":"2219_CR21","doi-asserted-by":"publisher","first-page":"105351","DOI":"10.1016\/j.drugpo.2026.105351","volume":"154","author":"L Picco","year":"2026","unstructured":"Picco L, Jung M, Fox F, et al. Provision of harm reduction services in community pharmacies: findings from an Australian national sample. Int J Drug Policy. 2026;154:105351. https:\/\/doi.org\/10.1016\/j.drugpo.2026.105351.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"2219_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.japh.2019.08.009","volume":"59","author":"S Kurian","year":"2003","unstructured":"Kurian S, Baloy B, Baird J, et al. Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians. J Am Pharm Assoc (2003). 2003;59(6):824\u201331. https:\/\/doi.org\/10.1016\/j.japh.2019.08.009.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2219_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy9020095","author":"SS McMillan","year":"2021","unstructured":"McMillan SS, Chan H, Hattingh LH. Australian community pharmacy harm-minimisation services: scope for service expansion to improve healthcare access. Pharmacy (Basel). 2021. https:\/\/doi.org\/10.3390\/pharmacy9020095.","journal-title":"Pharmacy (Basel)"},{"issue":"1-2","key":"2219_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.drugalcdep.2013.02.007","volume":"132","author":"AV Williams","year":"2013","unstructured":"Williams AV, Strang J, Marsden J. Development of Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) scales for take-home naloxone training evaluation. Drug Alcohol Depend. 2013;132(1\u20132):383\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.007.","journal-title":"Drug Alcohol Depend"},{"key":"2219_CR25","unstructured":"StataCorp. Stata Statistical Software: Release 18. College Station, TX: StataCorp LLC. 2023."},{"key":"2219_CR26","unstructured":"Monash University. Opioid Safety Toolkit. 2024. https:\/\/saferopioiduse.com.au. Accessed 21.07.2025."},{"key":"2219_CR27","unstructured":"Pharmaceutical Society of Australia. Opioid Safety Toolkit: Supporting your patients\u2019 safer prescription opioid use. 2026. https:\/\/www.psa.org.au\/opioidsafety\/. Accessed 11.03.2026."},{"key":"2219_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy10010024","author":"A Cid","year":"2022","unstructured":"Cid A, Patten A, Beazely M, et al. Protocol for the Optimizing Naloxone Dispensing in Pharmacies (ONDP) online continuing education program: a randomized controlled trial. Pharmacy (Basel). 2022. https:\/\/doi.org\/10.3390\/pharmacy10010024.","journal-title":"Pharmacy (Basel)"},{"issue":"1","key":"2219_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.japh.2019.06.016","volume":"60","author":"T Thakur","year":"2020","unstructured":"Thakur T, Frey M, Chewning B. Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review. J Am Pharm Assoc (2003). 2020;60(1):178\u201394. https:\/\/doi.org\/10.1016\/j.japh.2019.06.016.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2219_CR30","doi-asserted-by":"publisher","first-page":"105354","DOI":"10.1016\/j.drugpo.2026.105354","volume":"154","author":"AG McNeilage","year":"2026","unstructured":"McNeilage AG, Roxburgh A, Nielsen S, et al. Trends in Australian attitudes towards the availability of take-home naloxone: evidence from the National Drug Strategy Household Survey. Int J Drug Policy. 2026;154:105354. https:\/\/doi.org\/10.1016\/j.drugpo.2026.105354.","journal-title":"Int J Drug Policy"},{"key":"2219_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","volume":"57","author":"CE Paquette","year":"2018","unstructured":"Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104\u201310. https:\/\/doi.org\/10.1016\/j.drugpo.2018.04.004.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"2219_CR32","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1080\/08897077.2020.1809605","volume":"42","author":"D Rao","year":"2021","unstructured":"Rao D, Giannetti V, Kamal KM, et al. The relationship between knowledge, attitudes, and practices of community pharmacists regarding persons with substance use disorders. Subst Abus. 2021;42(4):630\u20137. https:\/\/doi.org\/10.1080\/08897077.2020.1809605.","journal-title":"Subst Abus"},{"issue":"5","key":"2219_CR33","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/09687637.2021.1936457","volume":"29","author":"SH Sulzer","year":"2022","unstructured":"Sulzer SH, Prevedel S, Barrett T, et al. Professional education to reduce provider stigma toward harm reduction and pharmacotherapy. Drugs Educ Prev Policy. 2022;29(5):576\u201386. https:\/\/doi.org\/10.1080\/09687637.2021.1936457.","journal-title":"Drugs Educ Prev Policy"},{"issue":"2","key":"2219_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/10511253.2022.2068632","volume":"34","author":"J Murphy","year":"2023","unstructured":"Murphy J, Russell B. Stigma reduction through addiction and naloxone education. J Crim Justice Educ. 2023;34(2):185\u201398. https:\/\/doi.org\/10.1080\/10511253.2022.2068632.","journal-title":"J Crim Justice Educ"},{"issue":"1","key":"2219_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12954-022-00589-6","volume":"19","author":"NA Bascou","year":"2022","unstructured":"Bascou NA, Haslund-Gourley B, Amber-Monta K, et al. Reducing the stigma surrounding opioid use disorder: evaluating an opioid overdose prevention training program applied to a diverse population. Harm Reduct J. 2022;19(1):5. https:\/\/doi.org\/10.1186\/s12954-022-00589-6.","journal-title":"Harm Reduct J"},{"issue":"5","key":"2219_CR36","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/dar.13855","volume":"43","author":"N Karthikeyan","year":"2024","unstructured":"Karthikeyan N, Xia T, Nielsen S, et al. Stocking and supplying naloxone: findings from a representative sample of community pharmacies in Victoria, Australia. Drug Alcohol Rev. 2024;43(5):1305\u201312. https:\/\/doi.org\/10.1111\/dar.13855.","journal-title":"Drug Alcohol Rev"},{"key":"2219_CR37","unstructured":"Penington Institute. Saving lives: Australian naloxone access model Melbourne: Penington Institute. 2018. ISBN: 978-0-9808778-3-0"},{"issue":"4S","key":"2219_CR38","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/j.japh.2019.06.011","volume":"59","author":"S Griffin","year":"2003","unstructured":"Griffin S, Wishart B, Bricker K, et al. Impact of a pharmacist-driven intervention on the outpatient dispensing of naloxone. J Am Pharm Assoc (2003). 2003;59(4S):S161\u20136. https:\/\/doi.org\/10.1016\/j.japh.2019.06.011.","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"2S","key":"2219_CR39","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.japh.2016.12.064","volume":"57","author":"PR Freeman","year":"2003","unstructured":"Freeman PR, Goodin A, Troske S, et al. Pharmacists\u2019 role in opioid overdose: Kentucky pharmacists\u2019 willingness to participate in naloxone dispensing. J Am Pharm Assoc (2003). 2003;57(2S):S28\u201333. https:\/\/doi.org\/10.1016\/j.japh.2016.12.064.","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"4","key":"2219_CR40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/dar.12812","volume":"37","author":"R Dwyer","year":"2018","unstructured":"Dwyer R, Olsen A, Fowlie C, et al. An overview of take-home naloxone programs in Australia. Drug Alcohol Rev. 2018;37(4):440\u20139. https:\/\/doi.org\/10.1111\/dar.12812.","journal-title":"Drug Alcohol Rev"},{"key":"2219_CR41","unstructured":"Australian Health Practitioner Regulation Agency Pharmacy Board. Pharmacy workforce: Snapshot as at 30 June 2023. 2023. https:\/\/www.pharmacyboard.gov.au\/About\/Health-profession-demographic-snapshot.aspx. Accessed 24.03.2026."},{"issue":"2","key":"2219_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11096-022-01523-3","volume":"45","author":"L Picco","year":"2023","unstructured":"Picco L, Lam T, Xia T, et al. Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists. Int J Clin Pharm. 2023;45(2):421\u20139. https:\/\/doi.org\/10.1007\/s11096-022-01523-3.","journal-title":"Int J Clin Pharm"},{"issue":"11s3","key":"2219_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1046\/j.1360-0443.95.11s3.5.x","volume":"95","author":"FK Del Boca","year":"2000","unstructured":"Del Boca FK, Noll JA. Truth or consequences: the validity of self\u2010report data in health services research on addictions. Addiction. 2000;95(11s3):347\u201360.","journal-title":"Addiction"},{"key":"2219_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy9010030","author":"A Cid","year":"2021","unstructured":"Cid A, Daskalakis G, Grindrod K, et al. What is known about community pharmacy-based take-home naloxone programs and program interventions? A scoping review. Pharmacy (Basel). 2021. https:\/\/doi.org\/10.3390\/pharmacy9010030.","journal-title":"Pharmacy (Basel)"},{"key":"2219_CR45","unstructured":"Australian Competition & Consumer Commission. Statement of Issues: Sigma Healthcare limited-proposed acquisition of CW Group Holdings Limited. ACCC. 2024."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02219-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02219-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02219-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:02:57Z","timestamp":1788642177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02219-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":45,"alternative-id":["2219"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02219-8","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no other relevant financial or non-financial competing interests to report.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Monash University Human Research Ethics Committee (Approval number: 45169).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants prior to their inclusion in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}